Echo Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014
Echo Therapeutics, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, total revenue was $0.02 million against $0.02 million last year. Loss from operations was $2.9 million against $4.9 million last year. Net loss for the third quarter of 2014 was $5.5 million, or $0.43 per basic and diluted share as compared to $5.2 million, or $0.49 per basic and diluted share, for the third quarter of 2013.
For the nine months, total revenue was $0.06 million against $0.07 million last year. Loss from operations was $9.5 million against $16.5 million last year. Net loss was $12.0 million, or $0.99 per basic and diluted share as compared to $15.6 million, or $2.06 per basic and diluted share last year.